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Abstract
Zaire ebolavirus, a member of family Filoviridae is the cause of hemorrhagic fever. Due to
lack of appropriate antiviral or vaccine, this disease is very lethal. In this study, we tried
to find epitopes for superficial glycoprotein and nucleoprotein of Zaire ebolavirus (that
have high antigenicity for MHC I, II and B cells) by using in silico methods and
immunoinformatics approach. By using CTLPred, SYFPEITHI and ProPred web appli-
cations for MHC class I and SYFPEITHI and ProPred1 web applications for MHC class
II, we had been able to find epitopes (peptides) that have the highest score. Also ElliPro,
IgPred and DiscoTope web tools had been performed to predict B cells conformational
epitopes. Linear epitope prediction for B cell was performed with six methods from
IEDB. All of the results that including candidate epitopes for T cells and B cells were
reported. It was expected that these peptides could be stimulated immune response and
used for designing the multipeptide vaccine against ZEV but these results should be
reliable with experimental analysis.
Keywords: epitopes, glycoprotein, immune response, immunoinformatics approach,
multipeptide vaccine, nucleoprotein, Zaire ebolavirus
1. Introduction
Zaire ebolavirus, a member of genus Ebola virus, family Filoviridae, and order Mononegavirales, is
enveloped, RNA negative strand genome and filamentous virus. This virus is the cause of serious
hemorrhagic fever (HF) in human and the mortality rate is 50–90% [1, 2]. There have been several
outbreaks of Ebola virus up to now and the last one was on 2014.This outbreak started in Guinea
and spread to other countries in West Africa. The 2014 outbreak was the largest one which had
the highest mortality rate and risk of spreading to different parts of the world [3, 4].
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Experimental work with EBOV is very difficult and currently, there is no effective and licensed
vaccine available for Ebola. Vaccination is a good approach for the prevention and treatment
against many types of diseases like the viral infection. There are several types of vaccines, and
the goal of all of them is presenting antigenic fragment to the immune system to induce the
adaptive immune response. Several types of antiviral vaccines consist of inactivated, live
attenuated, virus-like particles and DNA vaccines. Another type of vaccine is peptide-based
vaccines. These vaccines are based on designing different epitopes for B cells and T cells. These
vaccines, in comparison with other vaccines, have fewer side effects and are safe and easy to
prepare [4–6]. Obviously, T cells have an important role in stimulating immune responses, but
for having a better and accurate response, first of all, antigenic fragments should be attached to
major histocompatibility complex (MHC) molecules. MHC molecules process and present
antigenic peptides to T cells. These peptide epitopes must be linear for attaching to MHC
molecules [7]. The most of T cells are belonging to two groups namely CD8+ and CD4+. The
difference between two groups refers to different glycoproteins in the surface of T cells. CD8+ T
cells are cytotoxic T cells (CTL) that bind to MHC class I molecules and CD4+ T cells are T
helper cells that attach to MHC class II [8, 9]. B cells are another part of immune systems,
which have receptors and secrete antibodies. Epitopes can be discontinuous or continuous for
B cells. These epitopes can also bind to lipids, carbohydrates and peptides but 3D structure of
antigens has an important role in stimulating humoral immune response by B cells [10]. With
the advances in in silico method and bioinformatics, immunoinformatics, a branch of science
was progressed. Immunoinformatics is an interdisciplinary science that emanates from immu-
nology and bioinformatics and generates meaningful immunological data. With the help of
immunoinformatics approaches, we can find epitopes for B cells and T cells, and also we can
design vaccines based on peptide or multipeptide vaccine [4, 11].
In this chapter, we tried to use immunoinformatics tools and in silico method to predict MHCs
linear epitopes and B cells discontinuous and linear epitopes (peptides) for glycoprotein and
nucleoprotein of Zaire ebolavirus (as antigen). These results can be useful for finding epitopes
that can be the candidate for designing vaccine and therapeutic strategies for fighting with HF
(hemorrhagic fever) of Ebola virus.
2. The best candidate for producing vaccines against Ebola virus
The ZEOBV genome has seven ORF, including NP-VP35-VP40-GP-VP30-VP24-L. Nucleo-
protein (NP) causes encapsulation of the genome of Ebola. It has been aggregated with
VP30 (transcription factor) and VP35 (polymerase cofactor). L is RNA-dependent RNA
polymerase. VP24 is a minor matrix protein that associates with the membrane. VP40 is a
major matrix protein that can mediate virus particles creation [1, 4, 12]. Glycoprotein (GP)
is present on the surface of Ebola. Secreted nonstructural GP, structural GP 1 and GP 2 are
the results of mRNA editing during transcription of GP of ZEBOV. The N-terminal
sequence between the GP and sGP is the same but the C-terminal of them is different [4,
13]. The ratio between sGP and GP during infection is 80–20%. Superficial GP is cleaved
by furin in Golgi to GP1 and GP2 that form homotrimeric proteins on the surface of EBOV
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[5, 10]. The GP1 is a soluble protein on the surface of virus, which has a mucin-like
domain and is highly glycosylated.GP2 is a membrane-spanning subunit and smaller than
GP1, which is connected to GP1 by disulfide bonds [14]. GP has a major role in attaching
to host cells and has cytotoxicity effects. This polycistronic GP is the main difference
between ZEBOV and other mononegavirus. Because of the GP on the surface, this protein
has the most antigenicity for the immune system and so it can be the best candidate for
producing vaccines against EBOV [2, 4]. Immunoinformatic studies on Ebola virus pro-
teins also have shown that there is a high rate of immune response for epitopes of Ebola
nucleoprotein (NP), in which, it can be even more than the response for epitopes of Ebola
glycoprotein [15–18]. Therefore, it can be another target for peptide-based vaccine design-
ing against Ebola virus.
Bioinformatics evaluation on the superficial glycoprotein showed less than 30% identity with
family and less than 50% with species of identity in the this protein, this glycoprotein is also
glycosylated. Studies have been shown that the structure and sequencing of GP are constantly
changing and these changes are the major causes of the weakness of the immune system
against the virus and, consequently, its pathogenicity. For these reasons, designing and devel-
opment of the vaccine against the Ebola virus is difficult and complex.
3. Epitope mapping for the purpose of peptide-based vaccine design
The most commonly used assimilation and the concept of the term epitope mapping is the
mapping of the antigenic regions detected by antibodies. This term is ambiguous because the
purpose of using this term in research is not clear, and this mapping can be done with a variety
of goals. Therefore, researchers have tried to use alternative terms for epitope mapping in
articles in order to clarify the purpose of this bioinformatics process such as immunological
analysis, microstructure analysis and epitope determination. Despite all these efforts and
including a wide range of goals, scientists are still advised to use this term in articles and
resources.
A number of important applications of epitope mapping including:
• Determination of biological process mechanism,
• Recognition of an epitope of practical value,
• Connection of any type of polymorphism such as SNP to protein structure or Ab binding,
• Characterization of Ab binding in patients,
• Evaluation of vaccine design,
• Identification of autoimmune diseases,
• Qualification of an Ab for diagnostic use such as Western blot analysis, trans-species
assays, finding isoforms of Ag and allergen characterization,
• Distinguishing of antigen peptide mimic,
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• Establishing of antigen structure and
• Finding an antigen which it can make different between immunization antibodies and
infection antibodies.
Immunogenicity studies have shown epitope mapping (the branch of bioinformatics) is based
on mathematical modeling and evolutionary algorithms. Epitope mapping methods can be
used to molecular modeling behaviors in nature, so the data obtained from these methods can
predict molecular interactions, such as binding of antigen to antibody and peptide to MHC,
with high probability [19, 20].
Designing of vaccines based on peptides or epitopes is the goal that we have been consid-
ering in this study. They are within the epitope mapping compass and to achieve these
goals, we identify and predict the epitopic areas by using approved and high-performance
software.
Mathematically modeled methods for epitope mapping are artificial neural networks (ANN),
quantization matrices, decision trees, HMM (Markov secret models), SMM is a stabilized
matrix method (SMM), among which ANN, SVM and HMM are capable of analyzing linear
and nonlinear data. In many applications that analyze epitope prediction, these three methods
are used to identify the sequential linear epitopes of the T lymphocytes and the nonlinear
(spatial) epitopes of the B lymphocytes [4, 21, 22].
There are other predictive methods for detecting spatial epitopes of the B cell lymphocytes,
which include the following: homology modeling, docking, 3D- and threading techniques.
These methods with the ANN, SMM and HMM methods are most used in the study of the
spatial epitope and are among the software main methods used in this research [4, 23]. In sum,
all methods for identifying epitopes that have the best antigenic properties but the epitopes
should have important characteristics, including (1) structural flexibility, (2) in the surface of
the protein, (3) exposure to solvent, (4) containing charged amino acids and (5) contains
hydrophilic amino acids.
4. Candidate for designing peptide-based vaccines against Ebolavirus
Conventional vaccines are prepared from an attenuated or inactive version of the pathogen.
However, often the antigen to which the immune system responds is of small number of amino
acids or peptide of antigen. The alternative approach to stimulate the immune response, such
as humoral and cell-mediated immune response, is the identification of peptide sequences or
epitopes that have a protective immune response. Therefore, these epitopes can have no risk of
mutation and they would be more stable, and also, there can be fewer side effects [24, 25]. This
approach is called peptide-based vaccine designing.
4.1. Determine the T cell antigenic fragment
Epitope analysis was performed for MHC classes I and II.
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4.1.1. Epitopes analysis for MHC class I
By using CTLPred (http://www.imtech.res.in/raghava/ctlpred/index.html), SYFPEITHI (http://
www.syfpeithi.de/bin/MHCServer.dll/EpitopePrediction.htm) and ProPred1 (http://www.imtech.
res.in/raghava/propred/) web tools, we had been able to find some peptidic epitopes for MHC
class I.
A. Finding epitopes for MHC class I by using CTLPred web tool and sequence of GP and NP
of ZEBOV. In Tables 1 and 2, three peptides that have higher score are shown for each
protein. Positions 19, 245 and 130 for GP and positions 292, 263 [4] and 397 for NP have
higher scores, so these peptides have been suggested by the application to be epitopes.
B. Using SYFPEITHIweb tool for predicting epitopes.We investigated some alleles of theMHCI
for the protein of interest. According to these results, as is shown in Table 3, for GP 564, 246
and 205 positions have a higher score in this prediction web tools [4]. But when we investi-
gated other alleles, we had observed that the position 246 was the most repetitive of all and
had a high score. For NP, results are shown in Table 4, position 266 has the highest score.
C. ProPred1 was used to predict epitopes of GP and NP, which bind with the highest score
to MHC class I alleles. The peptide with highest score was selected and is shown in
Table 1. Epitope prediction of GP based on CTLPred web server.
Table 2. Epitope prediction of NP based on CTLPred web server.
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Tables 5 and 6. According to this result, the highest score belonged to position 264 for
the HLA-B*2705 allele for GP, and as shown in Table 6 for NP, positions 273 and 109 for
HLA-A20 allele have higher scores.
Finally with revision of all data that are achieved for MHC class I, we are able to conclude that
sequences: “TRKIRSEEL” (with position 298 for T residue), “SRFTPQFLL” (with position 246
for S residue) and “ETTQALQLF” (with position 561 for E residue) for GP [4], and sequences:
“RLHPLARTA” (with position 263 for first residue), “SRELDHLGL” (with position 360 for
Table 3. Epitopes with scores above 27 of GP for MHC class I according to SYFPEITHI web server.
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first residue) and “VKNEVNSFK” (with position 273 for first residue), have the highest score
and the most frequent within these analysis. Therefore, it can be a better candidate peptide
epitopes than other sequences.
4.1.2. Epitopes analysis for MHC class II
By using SYFPEITHI and ProPred web tools, some peptidic epitopes for MHC class II were
predicted.
Table 4. Epitopes with scores above 27 of NP for MHC class I according to SYFPEITHI web server.
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A. Using SYFPEITHI web tools, epitope mapping of the amino acid sequence of the GP and
NP of ZEBOV was performed. Accordingly, we investigated some alleles of MHC class II
for the protein of interest. Peptides that have higher score were selected and are shown in
Table 7 for GP and in Table 8 for NP. According to this result for GP, the highest score
belongs to position 135 with the score of 35 and after that, the position of 159 has a higher
Table 7. GP epitope prediction for MHC class II based on SYFPEITHI web server.
Table 5. Epitope prediction from GP for MHC class I by ProPred1 web tools (only top score peptides are shown).
Table 6. NP epitope prediction of MHC class I according to ProPred1 web server.
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score for the HLA-DRB1*0101 allele [4]. For NP, position 710 with score 38 have the
highest score.
B. ProPred web tool was used to predict epitopes. Peptide with the highest score was
selected and is shown in Table 9 for GP and in Table 10 for NP. This result for GP has
Table 8. NP epitope prediction for MHC class II based on SYFPEITHI web server.
Table 9. Epitope prediction of GP for MHC class II based on ProPred web server.
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been shown that the positions 158 and 26 have the highest score. These positions are very
frequent in reviewing other results. For NP positions, 149 and 200 have higher score
according to ProPred web server.
As a result for MHC class II for GP, sequences: “IILFQRTFSIPLGVI” (with position 24 for first
residue), “CRYVHKVSGTGPCAG” (with position 135 for the first residue) and “FFLYDTLAS”
(with position 158 for first the residue) [4] and for NP sequences: “FLSFASLFL” (with position
149 for the first residue), “NRFVTLDGQQFYWPV” (with position 710 for first residue) and
“FRLMRTNFL” (with position 200 for first residue) have the highest scores and the most
frequent within these analysis.
By considering these results for MHC classes I and II, we think these epitopes can activate the
cell-mediated immune response; therefore they can be used for producing peptide-based
vaccines.
4.2. Determine the B cell antigenic fragment
4.2.1. Prediction of linear (sequential) epitopes
In this section, six methods from IEDB were used for the prediction of linear epitopes. A
collection of methods to predict linear B cell epitopes based on sequence characteristics of the
antigen using amino acid scales and HMMs. These methods include the following:
Table 10. MHC class II epitope prediction for NP of according to ProPred web server.
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1. BepiPred Linear Epitope Prediction: BepiPred predicts the location of linear B cell epitopes
using a combination of a HMM and a propensity scale method [26].
2. Chou & Fasman Beta-Turn Prediction: This method is commonly used to predict beta
turns to the prediction of antibody epitopes.
3. Emini Surface Accessibility Prediction: The computation was based on surface accessibil-
ity scale on antibodies. The accessibility profile was achieved using the formulae
Sn = (n + 4 + i) (0.37)  6, where Sn is the surface probability, dn is the fractional surface
probability value, and i vary from 1 to 6. A hexapeptide sequence with Sn greater than 1.0
indicates an increased probability of existing on the surface [27].
4. Karplus & Schulz Flexibility Prediction: In this method, flexibility scale based on ability to
move protein segments. The calculation based on a flexibility scale is similar to classical
calculation, except that the center is the first amino acid of the six amino acids window
length, and there are three scales for describing flexibility instead of a single one [28].
5. Kolaskar & Tongaonkar Antigenicity: A semiempirical method that makes use of physi-
cochemical properties of amino acid residues and their frequencies of occurrence in
experimentally known segmental epitopes was developed to predict antigenic peptide
established on proteins. This method can predict antigenic peptide with about 75% accu-
racy [29].
6. Parker Hydrophilicity Prediction: In this method, hydrophilic scale based on peptide
retention times during high-performance liquid chromatography (HPLC) on a reversed-
phase column was formulated [30].
4.2.1.1. Linear epitopes prediction for GP
We performed all of six methods for the GP protein sequence and summarized its results in
Table 11.
Table 11. Conclusion results for B cell linear epitope prediction from GP protein sequence.
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4.2.1.2. Linear epitopes prediction for NP
Weperformedall of sixmethods for theNPprotein sequenceand summarized its results inTable12.
4.2.2. Prediction of discontinuous (conformational) epitopes
4.2.2.1. Discontinuous epitopes prediction for GP
For B cell epitope prediction, 3D structure of antigen is more important than linear sequence,
therefore, in this study, we used PDB ID of GP of ZEBOV.
By considering the structure of GP in PDB, we comprehended that “I” chain of protein has a
maximum length than other chains. Also, with investigating two epitopes that predicted for
MHCs molecules, we understood both of them are on the “I” chain. Therefore, this chain was
selected in this analysis.
A. Using ElliPro web tool, epitope mapping of the amino acid sequence of the GP of ZEBOV
was performed. PDB Id (3csy) and “I” chain was used for ElliPro tool. Results from this
prediction for linear epitopes have been shown that the sequence of the peptides from 31
to 64 and 255 to 310 had a higher score than the other part of the protein and are
illustrated in Figures 1–3 and Table 13 [4].
B. By using DiscoTope and 3D structure of GP of ZEV, we could find discontinuous epitopes.
These sequencesmay be near to each other in 3D conformation but far from each other in the
amino acid sequence or the first structure. In this study, we analyze the “I” chain from GP1
and we set the threshold on 7.7, upstream regions of the threshold have the positive
prediction. Two regions that are shown in Figure 4 have positive predictions but 261–310
regions have amore score and these scores for each amino acid are illustrated inTable 14 [4].
In Table 14, contact number indicates the number of amino acids that are next to each
amino acid. As much as the contact number is lower, it shows that our amino acids are
Table 12. Conclusion results for B cell linear epitope prediction from NP protein sequence.
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more external. For example, in this study, VAL residue in the 310th position had the
lowest contact number and was more external.
C. Using IgPred web tool, epitope mapping of the amino acid sequence of the GP of ZEBOV
was performed. The sequence of the chain “I” of glycoprotein was selected to study the
interaction with the antibodies IgG, IgE and IgA.
As illustrated in Table 15, different regions in this chain had a different score for IgG but the
end of the sequence had the highest score and was approximately 255–310 regions.
Figure 1. Discontinuous epitope(s) number one 3D structure for GP.
Figure 2. Discontinuous epitope(s) number two 3D structure for GP.
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Therefore, according to prediction with these web tools, 255–310 regions are the proper candi-
date for being epitope [4].
4.2.2.2. Discontinuous epitopes prediction for NP
No specific structure was found in the PDB for NP. Therefore, homology modeling of these
types of proteins is needed to determine their structures. This goal has been achieved with the
help of homology modeling, and its stages have been described below:
A. Template Selection: The template to be used in homology modeling should be based on
target-template alignment, and the template that most closely resembles with our protein
is selected as the template.
B. Model Building: The models are constructed using target-template alignment by ProMod3,
and the areas that are shared and conserved between the template and the target are copied
from the template on the model. The areas that are added or removed are rebuilt using
fragment library. Side chains are then remodeled. Finally, its overall geometry is determined,
but the loop areas are building with PROMOD-II.
Table 13. Three top scores predicted discontinuous epitope for B cell according to ElliPro web server.
Figure 3. Discontinuous epitope(s) number three 3D structure for GP.
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Table 14. The predicted epitope sequence from 261 to 310 discontinuous amino acids for B cell according to DiscoTope
web server.
Figure 4. The model 3D structure.
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C. Results: The SWISS-MODEL template library (SMTL version 2017-09-21, PDB release
2017-09-15) was searched with BLAST and HHBlits for evolutionarily related structures
matching the target sequence is presented in Table 16 and the model 3D structure is also
shown in Figure 4.
D. After building homology modeling, ElliPro web tool was performed to predict conforma-
tional epitopes of NP. These results are shown in Table 17 and (Figures 5 and 6).
Table 16. Details on the template search.
Table 15. Antibodies scores for sequence of “I” chain of GP according to IgPred web server.
Table 17. Top scores predicted discontinuous epitope for B cell according to ElliPro web server.
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5. Conclusion
The hemorrhagic fever (HF) is a lethal disease from ZEBOV that caused the death of many
people in Africa. The glycoprotein of ZEBOV is the only protein on the surface of the virus,
and has severe cytotoxicity effects, also nucleoprotein can stimulate the immune response,
stronger than GP, therefore, it was offered to design the vaccine against both of them [4, 13,
Figure 5. Discontinuous epitope(s) number one 3D structure for NP.
Figure 6. Discontinuous epitope(s) number two 3D structure for NP.
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16, 17].Vaccination is a good idea to prevent infection and limit the spreading of Ebola
virus. So far, several vaccines against Ebola glycoprotein have been tested on animals, but
no licensed vaccine has been reported in humans [31, 32]. There are several types of
vaccine, in which one of them is a peptide vaccine, and it is the goal of this analysis. These
vaccines are designed based on the epitopes fragment of antigens and they are safer and
easy to prepare. For T cells, these epitopes are linear and they must bind to MHC I
and MHC II at first, but for B cells, 3D conformation of antigens is very important so it
can be discontinuous epitopes [6]. These discontinuous epitopes may be near to each other
in the 3D conformation but far from each other in the amino acid sequence or first structure
[4, 10]. The experimental work on this virus is very difficult and biosafety level is 4. With
the help of immunoinformatics tools for vaccine design, the use of laboratory work is
reduced, and hence we save more expense and time. Immunoinformatics approach can
help us to predict T cell and B cell epitopes, and also have application in in silico vaccina-
tion. By predicting T cell and B cell epitopes, we can find the peptide that is useful for in
silico vaccination or for designing multipeptide vaccine [11]. By using ProPred, CTLPred,
SYFPEITHI and ProPred1 web tools for predicting the epitopes for T cells, we had been able
to introduce peptides that can be the candidate for designing multipeptide vaccines. With
the use of ElliPro, DiscoTope, IgPred web servers and linear epitope prediction methods
from IEDB predicting epitopes for B cells, and these peptides can induce the immune
response and design for the peptide-based vaccine. With the help of immunoinformatics
tools for predicting epitopes for T cells and B cells, we can design the multipeptide vaccine,
and this vaccine can include both epitopes from GP and NP, which is useful for increasing
immune response against Ebola virus. As conclusion for linear epitopes that bind to MHC I
“TRKIRSEEL,” “SRFTPQFLL” and “ETTQALQLF” peptides for GP [4], and “RLHPLA-
RTA,” “SRELDHLGL” and “VKNEVNSFK” peptides for NP are candidate epitopes. Also
for MHC class II: “IILFQRTFSIPLGVI,” “CRYVHKVSGTGPCAG” and “FFLYDTLAS” pep-
tides for GP and “FLSFASLFL,” “NRFVTLDGQQFYWPV” and “FRLMRTNFL” peptides
for NP have the highest scores and the most frequent within this analysis. For B cell linear
epitope prediction, results are shown in Tables 11 and 12. As a final result for conforma-
tional epitopes, we can only say, peptide sequence from 255 to 310 amino acids for GP has a
higher score. These peptides are able to be the candidate for the vaccine against Ebola virus.
It should be noted that these results just in in silico are valid and need laboratory (in vivo
and in vitro) confirmation.
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